Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TLA Targeted Immunotherapies
Sollentuna, Stockholm County, Sweden
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
TLA's Tailored Leukapheresis technology has demonstrated clinical efficacy in a Phase 1/2 trial for severe ulcerative colitis—>50% mucosal healing and safety profile comparable to controls. The ALS program is in late preclinical validation, with GMP manufacturing underway, and a first-in-human ALS trial is in preparation.
- Therapeutic areas
- GastroenterologyNeurologyRheumatology
- Modalities
- Medical deviceImmunotherapyApheresis therapy
- Industry
- Therapeutic Medical Devices
02
Partnerships
Ferring Pharmaceuticals (global option for IBD device outside China)QVQ (Netherlands, antibody engineering for ALS device)
Beyond the preview
Go deeper on TLA Targeted Immunotherapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLA Targeted Immunotherapies.